PE20011118A1 - (+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3h-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1h-quinolein-2-ona como compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto - Google Patents
(+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3h-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1h-quinolein-2-ona como compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuestoInfo
- Publication number
- PE20011118A1 PE20011118A1 PE2001000041A PE2001000041A PE20011118A1 PE 20011118 A1 PE20011118 A1 PE 20011118A1 PE 2001000041 A PE2001000041 A PE 2001000041A PE 2001000041 A PE2001000041 A PE 2001000041A PE 20011118 A1 PE20011118 A1 PE 20011118A1
- Authority
- PE
- Peru
- Prior art keywords
- chloro
- methyl
- compound
- alkyl
- cyclopropylmetil
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- -1 3-CHLORO-PHENYL Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000001093 anti-cancer Effects 0.000 title 1
- 238000000926 separation method Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 102100026802 72 kDa type IV collagenase Human genes 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical compound C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 abstract 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 abstract 1
- 101000889282 Homo sapiens Choline transporter-like protein 4 Proteins 0.000 abstract 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 abstract 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- FIULGFJIHJJXMT-UHFFFAOYSA-N [C]1[N]C=CC=C1 Chemical class [C]1[N]C=CC=C1 FIULGFJIHJJXMT-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000023715 cellular developmental process Effects 0.000 abstract 1
- 229950008696 farnesil Drugs 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
Abstract
SE REFIERE A (+)-6-[AMINO-(6-CLORO-PIRIDIN-3-IL)-(3-METIL-3H-IMIDAZOL-4-IL)-METIL]-4-(3-CLORO-FENIL)-1-CICLOPROPILMETIL-1H-QUINOLEIN-2-ONA. SE REFIERE TAMBIEN A UNA COMPOSICION QUE COMPRENDE ADEMAS AGENTE QUIMIOTERAPICO O INHIBIDORES DE METALOPROTEASA MMP2; INHIBIDORES DE MMP9, INHIBIDORES DE TRANSDUCCION DE SENALES, AGENTES ANTIPROLIFERATIVOS, AGENTES CAPACES DE BLOQUEAR CTL4; UN METODO PARA SEPARAR ENANTIOANMEROS (+) Y (-) DEL COMPUESTO DE FORMULA I DE LA MEZCLA RACEMICA, DONDE; R1 ES H, ALQUILO C1-C10; R2 ES HALO, CIANO, COOR15; R3 - R7 SON H, ALQUILO C1-C10, ALQUENILO C2-C10, ENTRE OTROS; Z ES HETEROCICLO AROMATICO DE 4-10 MIEMBROS; R9 ES -(CR13R14)t(IMIDAZOLILO), R9 ES (CR13R14)t(PIRIDINILO); R12 ES H, ALQUILO C1-C10, (CR13R14)t(CICLOALQUILO C3-C10), ENTRE OTROS; R13 Y R14 SON H, ALQUILO C1-C10; t ES 0-5; q ES 1-5; R15 NO ES H, R12; n ES 1-3 . UN METODO PARA SINTETIZAR ENANTIOMEROS (+), (-). EL COMPUESTO INHIBE FARNESIL TRANSFERASA ASI COMO EL DESARROLLO CELULAR ANORMAL Y PUEDE SER UTIL EN EL TRATAMIENTO DE CANCER DE PULMON, HUESO, PANCREAS, PIEL
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17771800P | 2000-01-21 | 2000-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20011118A1 true PE20011118A1 (es) | 2001-11-06 |
Family
ID=22649709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001000041A PE20011118A1 (es) | 2000-01-21 | 2001-01-17 | (+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3h-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1h-quinolein-2-ona como compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto |
Country Status (17)
Country | Link |
---|---|
US (1) | US6479513B2 (es) |
EP (1) | EP1248782A1 (es) |
JP (2) | JP2003520796A (es) |
AR (1) | AR029792A1 (es) |
AU (1) | AU2001214087A1 (es) |
BR (1) | BR0016986A (es) |
CA (1) | CA2398353C (es) |
CO (1) | CO5271702A1 (es) |
GT (1) | GT200100008A (es) |
HN (1) | HN2000000266A (es) |
MX (1) | MXPA02007153A (es) |
MY (1) | MY126069A (es) |
PA (1) | PA8508101A1 (es) |
PE (1) | PE20011118A1 (es) |
SV (1) | SV2002000291A (es) |
TN (1) | TNSN01009A1 (es) |
WO (1) | WO2001053289A1 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HN2000000266A (es) * | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
AU2002214056A1 (en) | 2000-11-21 | 2002-06-03 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting benzoheterocyclic derivatives |
WO2002051835A1 (en) | 2000-12-27 | 2002-07-04 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
WO2003006006A1 (en) * | 2001-07-09 | 2003-01-23 | The Regents Of The University Of California | Use of matrix metalloproteinase inhibitors to mitigate nerve damage |
US7408063B2 (en) | 2001-12-19 | 2008-08-05 | Janssen Pharmaceutica, N.V. | 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors |
ES2287466T3 (es) | 2002-03-22 | 2007-12-16 | Janssen Pharmaceutica N.V. | Derivados de 2-quinolinona y quinazolina de bencilimidazolil sustituidas como inhibidores de la farnesil transferasa. |
AU2003229688B2 (en) | 2002-04-15 | 2009-07-30 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
DK1585743T3 (da) * | 2002-12-19 | 2007-09-17 | Pfizer | 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme |
JP2007530654A (ja) * | 2004-03-30 | 2007-11-01 | ファイザー・プロダクツ・インク | シグナル伝達阻害剤の組合せ |
CA2563805C (en) | 2004-05-03 | 2012-11-13 | Janssen Pharmaceutica N.V. | Diastereoselective addition of lithiated n-methylimidazole on sulfinimines |
WO2005105784A1 (en) * | 2004-05-03 | 2005-11-10 | Janssen Pharmaceutica N.V. | Diastereoselective synthesis process for the preparation of imidazole compounds |
WO2005105783A1 (en) * | 2004-05-03 | 2005-11-10 | Janssen Pharmaceutica N.V. | Diastereoselective synthesis process with 6-bromo-4-(3-chlorophenyl)-2-methoxy-quinoline |
AU2005276135B2 (en) * | 2004-08-26 | 2011-04-28 | Pfizer Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
DK1784396T3 (da) * | 2004-08-26 | 2011-02-14 | Pfizer | Pyrazol-substituerede aminoheteroaryl-forbindelser som proteinkinase-inhibitorer |
CA2578075A1 (en) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
US20060107555A1 (en) * | 2004-11-09 | 2006-05-25 | Curtis Marc D | Universal snow plow adapter |
EP1926996B1 (en) | 2005-09-20 | 2011-11-09 | OSI Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20070213366A1 (en) | 2005-12-23 | 2007-09-13 | Justman Craig J | Treatment of Synucleinopathies |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
PL2056874T3 (pl) | 2006-08-21 | 2013-02-28 | Hoffmann La Roche | Leczenie nowotworu przeciwciałem przeciw VEGF |
US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
NZ593090A (en) | 2008-11-13 | 2013-06-28 | Link Medicine Corp | Azaquinolinone derivatives and uses thereof |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US20110217309A1 (en) | 2010-03-03 | 2011-09-08 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20110275644A1 (en) | 2010-03-03 | 2011-11-10 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
EP3383375A1 (en) | 2015-12-03 | 2018-10-10 | Agios Pharmaceuticals, Inc. | Mat2a inhibitors for treating mtap null cancer |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW349948B (en) * | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
ES2175137T3 (es) * | 1995-12-08 | 2002-11-16 | Janssen Pharmaceutica Nv | Derivados de (imidazol-5-il)metil-2-quinolinona como inhibidores de laproteina farnesil-transferasa. |
CN1314904A (zh) | 1998-08-27 | 2001-09-26 | 辉瑞产品公司 | 用作抗癌剂的炔基取代的喹啉-2-酮衍生物 |
SK11002001A3 (sk) * | 1999-02-11 | 2002-05-09 | Pfizer Products Inc. | Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky |
HN2000000266A (es) * | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
-
2000
- 2000-11-27 HN HN2000000266A patent/HN2000000266A/es unknown
- 2000-11-29 AU AU2001214087A patent/AU2001214087A1/en not_active Abandoned
- 2000-11-29 MX MXPA02007153A patent/MXPA02007153A/es active IP Right Grant
- 2000-11-29 JP JP2001553763A patent/JP2003520796A/ja active Pending
- 2000-11-29 CA CA002398353A patent/CA2398353C/en not_active Expired - Fee Related
- 2000-11-29 BR BR0016986-2A patent/BR0016986A/pt not_active Application Discontinuation
- 2000-11-29 EP EP00976213A patent/EP1248782A1/en not_active Withdrawn
- 2000-11-29 WO PCT/IB2000/001769 patent/WO2001053289A1/en not_active Application Discontinuation
- 2000-12-04 PA PA20008508101A patent/PA8508101A1/es unknown
- 2000-12-27 CO CO00097877A patent/CO5271702A1/es not_active Application Discontinuation
-
2001
- 2001-01-17 PE PE2001000041A patent/PE20011118A1/es not_active Application Discontinuation
- 2001-01-17 US US09/761,994 patent/US6479513B2/en not_active Expired - Fee Related
- 2001-01-18 AR ARP010100227A patent/AR029792A1/es unknown
- 2001-01-18 GT GT200100008A patent/GT200100008A/es unknown
- 2001-01-19 TN TNTNSN01009A patent/TNSN01009A1/fr unknown
- 2001-01-19 MY MYPI20010243A patent/MY126069A/en unknown
- 2001-01-22 SV SV2001000291A patent/SV2002000291A/es not_active Application Discontinuation
-
2007
- 2007-07-18 JP JP2007186597A patent/JP2007326868A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2003520796A (ja) | 2003-07-08 |
AR029792A1 (es) | 2003-07-16 |
CO5271702A1 (es) | 2003-04-30 |
MY126069A (en) | 2006-09-29 |
HN2000000266A (es) | 2001-05-21 |
US6479513B2 (en) | 2002-11-12 |
GT200100008A (es) | 2001-10-19 |
PA8508101A1 (es) | 2002-08-26 |
TNSN01009A1 (fr) | 2005-11-10 |
CA2398353C (en) | 2007-07-31 |
SV2002000291A (es) | 2002-07-16 |
US20020004514A1 (en) | 2002-01-10 |
MXPA02007153A (es) | 2002-12-13 |
WO2001053289A1 (en) | 2001-07-26 |
CA2398353A1 (en) | 2001-07-26 |
AU2001214087A1 (en) | 2001-07-31 |
EP1248782A1 (en) | 2002-10-16 |
BR0016986A (pt) | 2002-10-08 |
JP2007326868A (ja) | 2007-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20011118A1 (es) | (+)-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3h-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1h-quinolein-2-ona como compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto | |
UY26391A1 (es) | Inhibidores sglt2 de glucosidos de c-arilo y metodo | |
CO5700767A2 (es) | Procedimiento de tratamiento de rechazo de transplantes | |
BR0200782A (pt) | Compostos para o tratamento da isquemia | |
EP2325651A3 (en) | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | |
MY133996A (en) | Compounds for the treatment of ischemia | |
AP9901478A0 (en) | Compounds for the treatment of ischemia. | |
BG108225A (en) | Thiohydantoins and use thereof for treating diabetes | |
BR0215405A (pt) | Composições e processos de uso de collajolie | |
AR038563A1 (es) | Composicion de ziprasidona y controles sinteticos | |
BRPI0412975A (pt) | espuma penetrante para uso farmacêutico | |
RS20050311A (en) | Selected cgrp antagonists,method for production and use thereof as medicament | |
AR051446A1 (es) | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) | |
EP1590336A4 (en) | SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | |
MX2007006397A (es) | Derivados de tetrahidropirano. | |
MXPA02005173A (es) | Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea. | |
EP1208129A1 (en) | DERIVATIVE POLYURETHANE COMPOSITIONS AND THEIR METHODS OF MANUFACTURING | |
WO2003105767A8 (en) | ANTIFUNGAL PARENTERAL PRODUCTS | |
ATE416157T1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
CA2334257A1 (en) | Treatment of osteoporosis with ep2/ep4 receptor selective agonists | |
WO2005016883A3 (en) | Acrylamide derivatives as vla-1 integrin antagonists and uses thereof | |
AR032872A1 (es) | Composicion para aclarar la piel y el metodo de aplicacion | |
UY27203A1 (es) | Bencimidazoles útiles en el tratamiento de la disfunción sexual | |
EP1667976A4 (en) | Isoquinolinone POTASSIUM CHANNEL INHIBITORS | |
WO2005060960A3 (en) | Use of histamine to treat bone disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |